share_log

Organicell Regenerative Medicine Announces Expansion Into Health And Beauty Market

Organicell Regenerative Medicine Announces Expansion Into Health And Beauty Market

Organicell再生醫學公司宣佈進軍保健和美容市場
Benzinga Real-time News ·  2022/09/16 08:48

MIAMI, FL / ACCESSWIRE / September 16, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, announced today that the Company will expand into the skincare and haircare industries.

佛羅裏達州邁阿密/ACCESSWIRE/2022年9月16日/致力於開發創新生物療法和再生醫學的臨牀階段生物製藥公司Organicell Regenerative Medicine,Inc.(OTCQB:OCEL)今天宣佈,該公司將擴展到護膚和護髮行業。

On September 14, 2022 BeautyHealth's Hydrafacial (NASDAQ:SKIN) announced its new partnership with Organicell to create the first to market exosome booster for their patented Hydrafacial device. Organicell's science team will work with Hydrafacial to prove the efficacy of how this new booster application may reduce inflammation, increase collagen, and increase elastin while extending the benefits of a traditional Hydrafacial.

2022年9月14日,美容美容(納斯達克:Skin)宣佈與Organicell建立新的合作伙伴關係,為其專利水潤面部設備創造首個上市外體助推器。Organicell的科學團隊將與HydraFacial合作,證明這種新的助推劑應用程序如何在延長傳統HydraFacial的好處的同時,減少炎症、增加膠原蛋白和增加彈性蛋白的有效性。

Organicell's CEO, Matt Sinnreich, said "This partnership is the first of many we are working on in the aesthetic and hair space. Hydrafacial is its own market, and we have given them exclusivity for their applications, however, this partnership paves the way for our science team to start collecting data that may help prove the efficacy of our products on hair restoration and in various topical skincare and aftercare products.

Organicell的首席執行官Matt Sinnreich説:“這項合作是我們在美容和美髮領域開展的眾多合作項目中的第一項。Hydrafacial是它自己的市場,我們為它們的應用提供了獨家經營權,然而,這一合作關係為我們的科學團隊開始收集數據鋪平了道路,這些數據可能有助於證明我們的產品在頭髮修復以及各種局部護膚和後期護理產品中的有效性。

"Extracellular Vesicles (EVs) are anti-inflammatory in nature. Our patent pending process allows us to concentrate up to 600 billion EVs per milliliter which contain over 300 cytokines, chemokines and growth factors. Organicell's science team will be researching how certain characterizations of our extracellular vesicles may be able to be used in hair transplant procedures to expedite healing and reduce swelling. They will be looking into how our products can possibly take the place of a Platelet-Rich Plasma (PRP) procedure for hair restoration. And our clinical research team will gather data to see how our EVs may help reduce wrinkles and the early signs of aging."

細胞外小泡(EVS)本質上是抗炎的。我們的專利申請過程允許我們每毫升濃縮高達6000億個EVS,其中包含300多種細胞因子、趨化因子和生長因子。Organicell的科學團隊將研究我們細胞外小泡的某些特徵如何能夠用於頭髮移植程序,以加快癒合和減少腫脹。他們將研究我們的產品如何可能取代富血小板血漿(PRP)程序來修復頭髮。我們的臨牀研究團隊將收集數據,看看我們的EV如何幫助減少皺紋和衰老的早期跡象。

Sinnreich concluded, "This partnership is a great first step into the skincare space. We are honored that Hydrafacial trusted our science team enough to be their partner in this innovative new booster for their incredibly successful business. Now that the door is open, we can conduct the necessary research to prove our thesis on the rest of the applications which we believe the skincare and haircare market needs."

Sinnreich總結道:“這項合作是進入護膚領域的第一步。我們很榮幸HydraFacial能夠充分信任我們的科學團隊,成為他們在這項創新的新業務中的合作伙伴。現在大門已經打開,我們可以進行必要的研究,以證明我們在護膚和護髮市場需要的其餘應用上的論點。”

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論